4,200
edits
Catecholaminergic Polymorphic Ventricular Tachycardia: Difference between revisions
Catecholaminergic Polymorphic Ventricular Tachycardia (view source)
Revision as of 16:10, 25 January 2010
, 25 January 2010no edit summary
No edit summary |
mNo edit summary |
||
| Line 22: | Line 22: | ||
** the CASQ2 gene, coding for the calsequestrine protein: ([[w:OMIM|OMIM™]] link {{OMIM2|114251}}) (1-2 % of patients) | ** the CASQ2 gene, coding for the calsequestrine protein: ([[w:OMIM|OMIM™]] link {{OMIM2|114251}}) (1-2 % of patients) | ||
'''Treatment'''<cite> | '''Treatment'''<cite>sumitomo</cite> | ||
* Beta-blockers | * Beta-blockers | ||
* [[w:nl:Internal_Cardiac_Defibrillator|ICD]] implantation combined with beta-blockers in CPVT patients who survived a cardiac arrest or patients with syncope and/or documented sustained [[Ventricular Tachycardia|ventricular tachycardia]] despite beta-blocker therapy.<cite> | * [[w:nl:Internal_Cardiac_Defibrillator|ICD]] implantation combined with beta-blockers in CPVT patients who survived a cardiac arrest or patients with syncope and/or documented sustained [[Ventricular Tachycardia|ventricular tachycardia]] despite beta-blocker therapy.<cite>ACC2006</cite> | ||
* Surgical left cardiac sympathetic denervation in selected patients whose symptoms and/or ventricular arrhythmias are not controlled by pharmacologic therapy | * Surgical left cardiac sympathetic denervation in selected patients whose symptoms and/or ventricular arrhythmias are not controlled by pharmacologic therapy <cite>Wilde</cite><cite>Collura</cite> | ||
* Avoid competitive and other strenuous exercise | * Avoid competitive and other strenuous exercise | ||
| Line 35: | Line 35: | ||
#ACC2006 pmid=16935995 | #ACC2006 pmid=16935995 | ||
#sumitomo pmid=12482795 | #sumitomo pmid=12482795 | ||
#Wilde pmid=18463378 | |||
#Collura pmid=19467503 | |||
</biblio> | </biblio> | ||